0.031
0.00 (6.90%)
| Previous Close | 0.029 |
| Open | 0.029 |
| Volume | 936,381 |
| Avg. Volume (3M) | 1,627,446 |
| Market Cap | 44,606,516 |
| Price / Book | 10.53 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 |
| Operating Margin (TTM) | -349.02% |
| Diluted EPS (TTM) | -0.040 |
| Total Debt/Equity (MRQ) | 1.18% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | -7.20 M |
| Levered Free Cash Flow (TTM) | -2.85 M |
| Return on Assets (TTM) | -367.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | TRYPTAMINE FPO [TYP] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 1.0 |
| Average | -0.25 |
|
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 41.69% |
| % Held by Institutions | 0.72% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |